Details for Patent: 5,965,581
✉ Email this page to a colleague
Title: | Compositions for inhibiting platelet aggregation |
Abstract: | A composition is disclosed comprising about 0.25 mg/ml 2-S-(n-Butylsulfonylamino)-3 -[4-(4-(piperdin-4-yl)butyloxylphenyl]propionic acid, about 8 mg/ml sodium chloride, about 2.7 mg/ml sodium citrate dihydrate, about 0.16 mg/ml citric acid anhydrous, wherein the composition osmolality concentration is between about 250-310 mOsmol/kg and the pH is in the range of between 5.5-6.5. |
Inventor(s): | Gelotte; Karl M. (North Wales, PA) |
Assignee: | Merck & Co., Inc. (Rahway, NJ) |
Filing Date: | May 15, 1998 |
Application Number: | 09/079,776 |
Claims: | 1. A composition comprising about 0.25 mg/ml 2-S-(n-Butylsulonylamino)-3-[4-(4-(piperidin-4-yl)butyloxy)phenyl]propioni c acid, about 8 mg/ml sodium chloride, about 2.7 mg/ml sodium citrate dihydrate, about 0.16 mg/ml citric acid anhydrous, wherein composition osmolality concentration is between about 250-310 mOsmol/kg and pH is in the range of between 5.5-6.5. 2. A composition comprising about 0.05 mg/ml 2-S-(n-Butylsulfonylamino)-3-[4-(4-(piperidin-4-yl)butyloxy)phenyl]propion ic acid, about 9 mg/ml sodium chloride, about 0.54 mg/ml sodium citrate dihydrate, about 0.032 mg/ml citric acid anhydrous, wherein composition osmolality concentration is between about 255-345 mOsmol/kg and pH is in the range of between 5.5-6.5. 3. A composition formed by combining together about 0.28 mg/ml 2-S -(n-Butylsufonylamino)-3-[4-(4-(piperidin-4-yl)butyloxy)phenyl]propionic hydrochloride monohydrate, about 8 mg/ml sodium chloride, about 2.7 mg/ml sodium citrate dihydrate, and about 0.16 mg/ml citric acid anhydrous, wherein composition osmolality concentration is between about 250-310 mOsmol/kg and pH is in the range of between 5.5-6.5. 4. A composition formed by combining together about 0.056 mg/ml 2-S-(n-Butylsulfonylamino)-3-[4-(4-(piperidin-4-yl)butyloxy)phenyl]propion ic hydrochloride monohydrate, about 9 mg/ml sodium chloride, about 0.54 mg/ml sodium citrate dihydrate, and about 0.032 mg/ml citric acid anhydrous, wherein composition osmolality concentration is between about 255-345 mOsmol/kg and pH is in the range of between 5.5-6.5. 5. A method for inhibiting the aggregation of blood platelets in a patient, comprising intravenously treating the patient with a pharmaceutically effective amount of the composition of claim 1. 6. A method for inhibiting the aggregation of blood platelets in a patient, comprising intravenously treating the patient with a pharmaceutically effective amount of the composition of claim 2. 7. A composition formed by combining together about 0.28 mg/ml 2-S-(n-Butylsulfonylamino)-3-[4-(4-(piperidin-4-yl) butyloxy)phenyl]propionic acid hydrochloride monohydrate, about 8 mg/ml sodium chloride, about 2.7 mg/ml sodium citrate dihdrate, and about 0.16 mg/ml citric acid anhydrous, wherein composition osmolality concentration is between about 250-310 mOsmol/kg, and composition pH, adjusted if necessary with one or more pH adjusting agents, is in the range of between 5.5-6.5. 8. A composition formed by combining together about 0.056 mg/ml 2-S-(n-Butysulfonylamino)-3[4-(4-(piperidin-4-yl)butyloxy)phenyl]propronic acid hydrochloride monohydrate, about 9 mg/ml sodium chloride, about 0.54 mg/ml sodium citrate dihydrate, and about 0.032 mg/ml citric acid anhydrous, wherein composition osmolality concentration is between about 255-345 mOsmol/kg, and composition pH, adjusted if necessary with one or more pH adjusting agents, is in the range of between 5.5-6.5. |